Company / Interest Expense per Share
Ligand Pharmaceuticals, Inc. Interest Expense per Share History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense per Share
$0.04
FY2023
5-year range
$0.04 / $1.22
FY2019-FY2023
Trend
-63.9%
vs FY2022
Sector context
#34 of 43
Health Care
What the data says
Ligand Pharmaceuticals, Inc.'s interest expense per share of $0.04 is lower than 79% of companies in the Health Care sector (FY2023). Interest Expense per Share has declined for 5 consecutive years, from $2.28 in FY2018 to $0.04 in FY2023.
Based on SEC 10-K filings.
0.04 in FY2023 with a 5-year CAGR of -55.8%.
Improved from $1.22 to $0.04 over the past 2 years.
Health Care sector context is included.
Interest Expense per Share over time
Growth rates
- 3-Year CAGR
- -71.3%
- 5-Year CAGR
- -55.8%
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s interest expense per share has declined for 5 consecutive years.
- In FY2023, interest expense per share decreased 63.9% year-over-year.
- Ranks #34 out of 43 companies in the Health Care sector.
- Peak interest expense per share was recorded in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest Expense per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0.04 | -63.9% |
| FY2022 | $0.11 | -91.2% |
| FY2021 | $1.22 | -25.1% |
| FY2020 | $1.63 | -5.3% |
| FY2019 | $1.72 | -24.6% |
| FY2018 | $2.28 | +254.6% |
| FY2017 | $0.64 | -0.0% |
| FY2016 | $0.64 | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026